T2D and CV Risk Reduction: Future Management

June 12, 2019 12:51 pm

Future considerations for managing patients with type 2 diabetes and associated cardiovascular risk based on emerging data and clinical recommendations with SGLT2 inhibitors and GLP-1 agonists.

Category: News
About The Author
-
Previous

Hua Medicine – A Global Effort to Stop Diabetes
Next

EASD 2019 : Personalised Prevention Of CVD In T2D- Prof Alessandro Doria

Related Videos

Reversing-T2D-with-a-keto-diet-Diet-Doctor-Podcast-with-Dr.-Sarah-Hallberg

Reversing T2D with a keto diet — Diet Doctor Podcast with Dr. Sarah Hallberg

Low-carb-for-diabetes-A-transformation-Diet-Doctor-Podcast

Low carb for diabetes: A transformation — Diet Doctor Podcast

Mechanisms-of-Action-of-GLP-1-Agonists-in-T2D

Mechanisms of Action of GLP-1 Agonists in T2D

Cardiologists-Perspective-of-Diabetes-and-Cardiovascular-Risk-Management-in-Post-ACS-T2D-patients

Cardiologist’s Perspective of Diabetes and Cardiovascular Risk Management in Post-ACS T2D patients

Preview-A-low-carb-diet-for-T2D-reversal-Dr.-Sarah-Hallberg

[Preview] A low-carb diet for T2D reversal – Dr. Sarah Hallberg

Team-based-care-for-patients-with-T2D-and-kidney-disease-Katherine-R-Tuttle-Jay-H-Shubrook

Team-based care for patients with T2D and kidney disease | Katherine R Tuttle & Jay H Shubrook